GIP-R
45 programs · 43 companies
Programs
45
Companies
43
Active Trials
29
Targeting GIP-R
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | CKDHeart Failure | |
| RHH-3592 | Roche | Phase 1/2 | CKDObesity | |
| AZN-5978 | AstraZeneca | Phase 2/3 | ALS | |
| Ivotuximab | GSK | NDA/BLA | Bladder CaPancreatic Ca | |
| Elrarapivir | Regeneron | Phase 1 | FSGSHS | |
| Capifutibatinib | Intra-Cellular | Phase 3 | MelanomaRB | |
| TNG-8610 | Tango Ther | NDA/BLA | ALSRB | |
| Pemicagene | Taysha Gene | Phase 2 | HNSCC | |
| UCB-7696 | UCB | NDA/BLA | SCLC | |
| 600-6147 | Jiangsu Hengrui | Preclinical | MGACC | |
| Rilutenlimab | Otsuka | Phase 2 | SMAHemophilia A | |
| HCM-8303 | Hutchmed | Phase 2 | Wet AMD | |
| Riluratamab | Akeso | Phase 2 | CKD | |
| DAN-IIT-482 | Dana-Farber | Phase 2 | UC | |
| NCI-IIT-415 | NCI | Preclinical | Heart Failure | |
| GIM-IIT-548 | GIMEMA | Phase 3 | HCC | |
| MOR-3625 | MorphoSys (Novartis) | NDA/BLA | Ovarian CaCervical Ca | |
| APL-1567 | Applied Ther | Approved | ALL | |
| Elratenlimab | Diffusion Pharma | Phase 3 | Gastric Ca | |
| NEU-3101 | Neumedicines | NDA/BLA | Asthma | |
| XBI-3618 | XBiotech | Phase 1 | CholangiocarcinomaALS | |
| TUR-3071 | Turning Point (BMS) | NDA/BLA | PAHRB | |
| BCY-7343 | Bicycle Therapeutics | Phase 2/3 | MyelofibrosisHNSCC | |
| BCY-3228 | Bicycle Therapeutics | Preclinical | Meso | |
| Tixatenlimab | ObsEva (XOMA) | Approved | SCDUC | |
| Lirarelsin | ObsEva (XOMA) | Approved | Pancreatic CaMDS | |
| Cevitapinarof | MediciNova | Phase 2/3 | Endometrial CaAngelman | |
| 601-626 | Shanghai Pharma | Approved | Gastric CaWM | |
| Pexafotisoran | Aimmune (Nestle) | Phase 1/2 | Parkinson's | |
| PRO-1192 | Proteon (Charles River) | Phase 1 | FL | |
| 225-3371 | Sirnaomics | Approved | DLBCL | |
| Nirarapivir | RemeGen | Approved | MDDTTR Amyloidosis | |
| Bemasotorasib | Dicerna (Novo) | Phase 1/2 | PAH | |
| Pexavorutinib | Daiichi Sankyo EU | Preclinical | MCL | |
| Pexaderotide | Genus | NDA/BLA | Rett | |
| ALK-9856 | ALK-Abello | Approved | T2DEoE | |
| Liracapivasertib | Hypera Pharma | Phase 1 | MCCMyelofibrosis | |
| BIO-IIT-588 | Bio Farma | Approved | PSP | |
| NAT-IIT-296 | Natl Cancer Ctr Singapore | Preclinical | NB | |
| RUI-IIT-209 | Ruijin Hospital | Preclinical | Thymoma | |
| RAB-IIT-774 | Rabin Medical Center | Phase 2 | OCD | |
| 002-2150 | Kelun Pharma | Phase 2 | CFCML | |
| Doxafotisoran | Bio-Techne | Phase 1 | SMAMCC | |
| BRK-4512 | Bruker | Preclinical | MGPAH | |
| Sovavorutinib | Stada Arzneimittel | Phase 2 | DLBCL |